Central Pathology Review in SENTIX, a Prospective Observational
International Study on Sentinel Lymph Node Biopsy in Patients
with Early-Stage Cervical Cancer (ENGOT-CX2)

J 2020

Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2)

NEMEJCOVA, K.; R. KOCIAN; C. KOHLER; Jiří JARKOVSKÝ; J. KLAT et. al.

Základní údaje

Originální název

Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2)

Autoři

Vydání

Cancers, BASEL, MDPI, 2020, 2072-6694

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.639

Kód RIV

RIV/00216224:14110/20:00116028

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.3390/cancers12051115

UT WoS

000539246000056

EID Scopus

2-s2.0-85085039460

Klíčová slova anglicky

sentinel lymph node; cervical cancer; metastases

Štítky

14110411, 14119612, GPK, GPKonko, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 12. 5. 2021 13:16, Mgr. Tereza Miškechová

Anotace

V originále

The quality of pathological assessment is crucial for the safety of patients with cervical cancer if pelvic lymph node dissection is to be replaced by sentinel lymph node (SLN) biopsy. Central pathology review of SLN pathological ultrastaging was conducted in the prospective SENTIX/European Network of Gynaecological Oncological Trial (ENGOT)-CX2 study. All specimens from at least two patients per site were submitted for the central review. For cases with major or critical deviations, the sites were requested to submit all samples from all additional patients for second-round assessment. From the group of 300 patients, samples from 83 cases from 37 sites were reviewed in the first round. Minor, major, critical, and no deviations were identified in 28%, 19%, 14%, and 39% of cases, respectively. Samples from 26 patients were submitted for the second-round review, with only two major deviations found. In conclusion, a high rate of major or critical deviations was identified in the first round of the central pathology review (28% of samples). This reflects a substantial heterogeneity in current practice, despite trial protocol requirements. The importance of the central review conducted prospectively at the early phase of the trial is demonstrated by a substantial improvement of SLN ultrastaging quality in the second-round review.

Citovat

NEMEJCOVA, K.; R. KOCIAN; C. KOHLER; Jiří JARKOVSKÝ; J. KLAT; A. BERJON; R. PILKA; B. SEHNAL; B. GIL-IBANEZ; E. LUPO; A. PETIZ; O. A. SANCHEZ; P. KASCAK; F. MARTINELLI; A. BUDA; J. PRESL; M. BARAHONA; L. VAN LONHUIJZEN; W. SZATKOWSKI; Luboš MINÁŘ; M. PAKIZ; P. HAVELKA; C. ZORRERO; M. MISIEK; L. C. SNYMAN; D. WYDRA; I. VERGOTE; A. VINNYTSKA; M. REDECHA; M. MICHAL; S. TINGULSTAD; B. KIPP; G. SZEWCZYK; R. TOTH; F. J .D. GARCIA; P. J. C. MARTIN; R. POKA; K. TAMUSSINO; M. LUYCKX; M. FASTREZ; J. C. STARINGER; A. GERMANOVA; A. PLAIKNER; S. BAJSOVA; P. DUNDR; N. MALLMANN-GOTTSCHALK a D. CIBULA. Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2). Cancers. BASEL: MDPI, 2020, roč. 12, č. 5, s. 1-13. ISSN 2072-6694. Dostupné z: https://doi.org/10.3390/cancers12051115.

@article{1670618,
   author = {Nemejcova, K. and Kocian, R. and Kohler, C. and Jarkovský, Jiří and Klat, J. and Berjon, A. and Pilka, R. and Sehnal, B. and GilandIbanez, B. and Lupo, E. and Petiz, A. and Sanchez, O. A. and Kascak, P. and Martinelli, F. and Buda, A. and Presl, J. and Barahona, M. and van Lonhuijzen, L. and Szatkowski, W. and Minář, Luboš and Pakiz, M. and Havelka, P. and Zorrero, C. and Misiek, M. and Snyman, L. C. and Wydra, D. and Vergote, I. and Vinnytska, A. and Redecha, M. and Michal, M. and Tingulstad, S. and Kipp, B. and Szewczyk, G. and Toth, R. and Garcia, F. J .D. and Martin, P. J. C. and Poka, R. and Tamussino, K. and Luyckx, M. and Fastrez, M. and Staringer, J. C. and Germanova, A. and Plaikner, A. and Bajsova, S. and Dundr, P. and MallmannandGottschalk, N. and Cibula, D.},
   article_location = {BASEL},
   article_number = {5},
   doi = {https://doi.org/10.3390/cancers12051115},
   keywords = {sentinel lymph node; cervical cancer; metastases},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2)},
   url = {https://www.mdpi.com/2072-6694/12/5/1115},
   volume = {12},
   year = {2020}
}

TY  - JOUR
ID  - 1670618
AU  - Nemejcova, K. - Kocian, R. - Kohler, C. - Jarkovský, Jiří - Klat, J. - Berjon, A. - Pilka, R. - Sehnal, B. - Gil-Ibanez, B. - Lupo, E. - Petiz, A. - Sanchez, O. A. - Kascak, P. - Martinelli, F. - Buda, A. - Presl, J. - Barahona, M. - van Lonhuijzen, L. - Szatkowski, W. - Minář, Luboš - Pakiz, M. - Havelka, P. - Zorrero, C. - Misiek, M. - Snyman, L. C. - Wydra, D. - Vergote, I. - Vinnytska, A. - Redecha, M. - Michal, M. - Tingulstad, S. - Kipp, B. - Szewczyk, G. - Toth, R. - Garcia, F. J .D. - Martin, P. J. C. - Poka, R. - Tamussino, K. - Luyckx, M. - Fastrez, M. - Staringer, J. C. - Germanova, A. - Plaikner, A. - Bajsova, S. - Dundr, P. - Mallmann-Gottschalk, N. - Cibula, D.
PY  - 2020
TI  - Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2)
JF  - Cancers
VL  - 12
IS  - 5
SP  - 1-13
EP  - 1-13
PB  - MDPI
SN  - 20726694
KW  - sentinel lymph node
KW  - cervical cancer
KW  - metastases
UR  - https://www.mdpi.com/2072-6694/12/5/1115
L2  - https://www.mdpi.com/2072-6694/12/5/1115
N2  - The quality of pathological assessment is crucial for the safety of patients with cervical cancer if pelvic lymph node dissection is to be replaced by sentinel lymph node (SLN) biopsy. Central pathology review of SLN pathological ultrastaging was conducted in the prospective SENTIX/European Network of Gynaecological Oncological Trial (ENGOT)-CX2 study. All specimens from at least two patients per site were submitted for the central review. For cases with major or critical deviations, the sites were requested to submit all samples from all additional patients for second-round assessment. From the group of 300 patients, samples from 83 cases from 37 sites were reviewed in the first round. Minor, major, critical, and no deviations were identified in 28%, 19%, 14%, and 39% of cases, respectively. Samples from 26 patients were submitted for the second-round review, with only two major deviations found. In conclusion, a high rate of major or critical deviations was identified in the first round of the central pathology review (28% of samples). This reflects a substantial heterogeneity in current practice, despite trial protocol requirements. The importance of the central review conducted prospectively at the early phase of the trial is demonstrated by a substantial improvement of SLN ultrastaging quality in the second-round review.
ER  -

NEMEJCOVA, K.; R. KOCIAN; C. KOHLER; Jiří JARKOVSKÝ; J. KLAT; A. BERJON; R. PILKA; B. SEHNAL; B. GIL-IBANEZ; E. LUPO; A. PETIZ; O. A. SANCHEZ; P. KASCAK; F. MARTINELLI; A. BUDA; J. PRESL; M. BARAHONA; L. VAN LONHUIJZEN; W. SZATKOWSKI; Luboš MINÁŘ; M. PAKIZ; P. HAVELKA; C. ZORRERO; M. MISIEK; L. C. SNYMAN; D. WYDRA; I. VERGOTE; A. VINNYTSKA; M. REDECHA; M. MICHAL; S. TINGULSTAD; B. KIPP; G. SZEWCZYK; R. TOTH; F. J .D. GARCIA; P. J. C. MARTIN; R. POKA; K. TAMUSSINO; M. LUYCKX; M. FASTREZ; J. C. STARINGER; A. GERMANOVA; A. PLAIKNER; S. BAJSOVA; P. DUNDR; N. MALLMANN-GOTTSCHALK a D. CIBULA. Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2). \textit{Cancers}. BASEL: MDPI, 2020, roč.~12, č.~5, s.~1-13. ISSN~2072-6694. Dostupné z: https://doi.org/10.3390/cancers12051115.

Přehled o publikaci